Manish  Potti net worth and biography

Manish Potti Biography and Net Worth

Director of Ocugen
Manish is Co-Founder and President of Innogenix Pharma, a generic pharmaceutical R&D and manufacturing company focused on solid oral dosage formulations, based in Long Island, New York.

He was previously Director of Business Development at Epic Pharma, a generic pharmaceutical company and CMO. While at Epic Pharma, he lead the M&A sale process in which the company was sold to Humanwell Healthcare of China in 2016.

Manish is actively involved in venture capital investing, in his capacity as CIO for a multi-family office. Areas of investment focus include: Generic pharmaceutical injectables, ophthalmic, topical, liquid, nasal, and solid oral dosage forms; Biotech from startup to public equity; and medical devices.

Prior to his experience in pharmaceuticals, Manish spent several years in finance as an analyst and trader, working in investment banking and hedge funds. He has experience investing across a variety of asset classes and strategies.

Manish holds a Bachelors of Science in Cellular and Molecular Biology from The Johns Hopkins University and a Masters Degree in Financial Engineering from New York University.

How do I contact Manish Potti?

The corporate mailing address for Mr. Potti and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Manish Potti's contact information.

Has Manish Potti been buying or selling shares of Ocugen?

Manish Potti has not been actively trading shares of Ocugen within the last three months. Most recently, Manish Potti sold 68,185 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $8.86, for a transaction totalling $604,119.10. Learn More on Manish Potti's trading history.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Manish Potti Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2021Sell68,185$8.86$604,119.10View SEC Filing Icon  
See Full Table

Manish Potti Buying and Selling Activity at Ocugen

This chart shows Manish Potti's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.90
Low: $0.89
High: $0.92

50 Day Range

MA: $0.99
Low: $0.87
High: $1.21

2 Week Range

Now: $0.90
Low: $0.36
High: $2.11

Volume

209,519 shs

Average Volume

6,075,129 shs

Market Capitalization

$261.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75